

Jeffrey A Allen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1798345/publications.pdf>

Version: 2024-02-01

30
papers

1,037
citations

471509

17
h-index

501196

28
g-index

32
all docs

32
docs citations

32
times ranked

693
citing authors

#	ARTICLE	IF	CITATIONS
1	Could posturography be a useful outcome measure for chronic inflammatory demyelinating polyneuropathy?. <i>Muscle and Nerve</i> , 2022, 65, 7-9.	2.2	0
2	A Global Survey of Disease Burden in Patients Who Carry a Diagnosis of Chronic Inflammatory Demyelinating Polyneuropathy. <i>Advances in Therapy</i> , 2021, 38, 316-328.	2.9	6
3	Quantifying Treatment-Related Fluctuations in CIDP. <i>Neurology</i> , 2021, 96, e1876-e1886.	1.1	15
4	Misdiagnosis and diagnostic pitfalls of chronic inflammatory demyelinating polyradiculoneuropathy. <i>European Journal of Neurology</i> , 2021, 28, 2065-2073.	3.3	23
5	Patient Preferences for Subcutaneous versus Intravenous Administration of Treatment for Chronic Immune System Disorders: A Systematic Review. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 811-834.	1.8	32
6	Measuring treatment response to chronic inflammatory demyelinating polyneuropathy in clinical practice: More than just asking. <i>Muscle and Nerve</i> , 2021, 64, 1-3.	2.2	6
7	European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Forceâ€”Second revision. <i>Journal of the Peripheral Nervous System</i> , 2021, 26, 242-268.	3.1	176
8	Outcome measures and biomarkers in chronic inflammatory demyelinating polyradiculoneuropathy: from research to clinical practice. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 805-816.	2.8	6
9	European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Forceâ€”Second revision. <i>European Journal of Neurology</i> , 2021, 28, 3556-3583.	3.3	153
10	Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG?. <i>Journal of the Neurological Sciences</i> , 2020, 408, 116497.	0.6	21
11	Fatigue in chronic inflammatory demyelinating polyneuropathy. <i>Muscle and Nerve</i> , 2020, 62, 673-680.	2.2	12
12	The Misdiagnosis of CIDP: A Review. <i>Neurology and Therapy</i> , 2020, 9, 43-54.	3.2	25
13	Monitoring Clinical Course and Treatment Response in Chronic Inflammatory Demyelinating Polyneuropathy During Routine Care. <i>JAMA Neurology</i> , 2020, 77, 1159.	9.0	26
14	Updated cerebrospinal fluid total protein reference values improve chronic inflammatory demyelinating polyneuropathy diagnosis. <i>Muscle and Nerve</i> , 2019, 60, 180-183.	2.2	37
15	Challenges in the diagnosis of chronic inflammatory demyelinating polyneuropathy. <i>Brain and Behavior</i> , 2018, 8, e00932.	2.2	26
16	Individualized immunoglobulin therapy in chronic immuneâ€”mediated peripheral neuropathies*. <i>Journal of the Peripheral Nervous System</i> , 2018, 23, 78-87.	3.1	21
17	Risk factors for the development of paclitaxelâ€”induced neuropathy in breast cancer patients. <i>Journal of the Peripheral Nervous System</i> , 2018, 23, 129-133.	3.1	26
18	Reply. <i>Muscle and Nerve</i> , 2018, 57, E132-E133.	2.2	0

#	ARTICLE	IF	CITATIONS
19	Electrodiagnostic errors contribute to chronic inflammatory demyelinating polyneuropathy misdiagnosis. <i>Muscle and Nerve</i> , 2018, 57, 542-549.	2.2	56
20	Total spinal and brainstem anesthesia as complication of paravertebral ropivacaine administration. <i>Neurology: Clinical Practice</i> , 2017, 7, 430-432.	1.6	4
21	Chronic Demyelinating Polyneuropathies. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2017, 23, 1310-1331.	0.8	8
22	Optimizing the Use of Outcome Measures in Chronic Inflammatory Demyelinating Polyneuropathy. <i>US Neurology</i> , 2017, 13, 26.	0.2	8
23	Improving the management of chronic inflammatory demyelinating polyradiculoneuropathy. <i>Neurodegenerative Disease Management</i> , 2016, 6, 237-247.	2.2	2
24	Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. <i>Muscle and Nerve</i> , 2016, 53, 165-168.	2.2	24
25	Acquired Immunologic Neuropathies. <i>Seminars in Neurology</i> , 2015, 35, 398-406.	1.4	5
26	CIDP diagnostic pitfalls and perception of treatment benefit. <i>Neurology</i> , 2015, 85, 498-504.	1.1	188
27	Optimizing IgG therapy in chronic autoimmune neuropathies: A hypothesis driven approach. <i>Muscle and Nerve</i> , 2015, 51, 315-326.	2.2	33
28	Gastrostomy tube placement by endoscopy versus radiologic methods in patients with ALS: A retrospective study of complications and outcome. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2013, 14, 308-314.	1.7	49
29	Reversible demyelinating neuropathy associated with renal cell carcinoma. <i>Neuromuscular Disorders</i> , 2011, 21, 227-231.	0.6	8
30	Ocular myasthenia gravis in a senior population: Diagnosis, therapy, and prognosis. <i>Muscle and Nerve</i> , 2010, 41, 379-384.	2.2	41